CML

conference reporter by Neil P. Shah, MD, PhD

Although great progress has been made in the treatment of chronic phase chronic myeloid leukemia (CML), many patients still experience intolerance ......READ MORE

Paroxysmal Nocturnal Hemoglobinuria

conference reporter by Carlos M. de Castro III, MD

Data from several studies presented at the 64th ASH Annual Meeting and Exposition highlight the promise of proximal complement inhibition in the tr......READ MORE

Paroxysmal Nocturnal Hemoglobinuria

conference reporter by Carlos M. de Castro III, MD

Researchers at the 64th ASH Annual Meeting and Exposition presented data from several studies evaluating the treatment of paroxysmal nocturnal hemo......READ MORE

CML

conference reporter by Neil P. Shah, MD, PhD

At the 64th ASH Annual Meeting and Exposition, emerging data underscored the importance of tyrosine kinase inhibitor (TKI) tolerability and dose op......READ MORE

CML

conference reporter by Hagop M. Kantarjian, MD

The treatment of chronic phase chronic myeloid leukemia (CML) is evolving in response to newer data on BCR::ABL1 tyrosine kinase inhibitors (TKIs).......READ MORE